Multiple Sclerosis Relapses Following Cessation of Fingolimod
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F22%3A10443036" target="_blank" >RIV/00064165:_____/22:10443036 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/22:10443036
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=ytPtKRErVP" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=ytPtKRErVP</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s40261-022-01129-7" target="_blank" >10.1007/s40261-022-01129-7</a>
Alternative languages
Result language
angličtina
Original language name
Multiple Sclerosis Relapses Following Cessation of Fingolimod
Original language description
Background: There is growing interest in the issue of disease reactivation in multiple sclerosis following fingolimod cessation. Relatively little is known about modifiers of the risk of post-cessation relapse, including the delay to commencement of new therapy and prior disease activity. Objective: We aimed to determine the rate of relapse following cessation of fingolimod and to identify predictors of relapse following cessation. Methods: Data were extracted from the MSBase registry in March 2019. Inclusion criteria were (a) clinically definite relapsing multiple sclerosis, (b) treatment with fingolimod for >= 12 months, (c) follow-up after cessation for >= 12 months, and (d) at least one Expanded Disability Status Scale score recorded in the 12 months before cessation. Results: A total of 685 patients were identified who met criteria. The mean annualised relapse rate was 1.71 (95% CI 1.59, 1.85) in the year prior to fingolimod, 0.50 (95% CI 0.44, 0.55) on fingolimod and 0.43 (95% CI 0.38, 0.49) after fingolimod. Of these, 218 (32%) patients experienced a relapse in the first 12 months. Predictors of a higher relapse rate in the first year were: younger age at fingolimod cessation, higher relapse rate in the year prior to cessation, delaying commencement of new therapy and switching to low-efficacy therapy. Conclusions: Disease reactivation following fingolimod cessation is more common in younger patients, those with greater disease activity prior to cessation and in those who switch to a low-efficacy therapy.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30103 - Neurosciences (including psychophysiology)
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Clinical Drug Investigation
ISSN
1173-2563
e-ISSN
1179-1918
Volume of the periodical
42
Issue of the periodical within the volume
4
Country of publishing house
NZ - NEW ZEALAND
Number of pages
10
Pages from-to
355-364
UT code for WoS article
000770497300001
EID of the result in the Scopus database
2-s2.0-85127113710